RespirAI Enters Into Know-How Agreement With Mayo Clinic for Development of AI Respiratory Platform

 RespirAI Medical, a digital startup company based in Israel, has announced it has entered into a collaboration with Mayo Clinic for developing a wearable AI-based home monitoring platform for respiratory diseases. This endeavor aims to improve patient care by creating a comprehensive platform that closely monitors the rehabilitation process of Chronic obstructive pulmonary disease (COPD) patients who have undergone the Zephyr Valve procedure.

Recommended AI News: Marketers More Confident about their Generative AI Options; Abandoning Metaverse Plans

RespirAI Medical is committed to the management chronic health conditions, with a strong focus on pulmonology. RespirAI’s innovative platform, driven by proprietary biomarkers, empowers patients to accurately monitor their disease in real-time from the comfort of their homes. It allows for the detection of disease exacerbations early on, which can potentially enhance disease management, medication adherence, reduce the need for in-person visits, and could save lives while lowering healthcare costs.

Nimrod Bin-Nun, Co-Founder & CEO of RespirAI, shared his enthusiasm for this collaboration stating, “Our collaboration with Mayo Clinic represents a significant likelihood and step forward in improving the lives of patients suffering from chronic conditions. It is an exceptional opportunity to combine new technology with established medical expertise. We firmly believe that by working together, we can reshape the patient experience and outcomes, providing better, more efficient care.”

The focal point of this collaboration is the Zephyr Valve procedure, a minimally invasive treatment option for individuals with Chronic Obstructive Pulmonary Disease (COPD). To date, approximately 25,000 individuals worldwide have benefited from this innovative treatment. Thorough at-home patient monitoring, including tracking of physical activity and early detection of potential complications can play an important role in mitigating risks and ensuring the Zephyr Valve procedure’s success. Timely initiation of appropriate treatment is critical for achieving the best possible outcomes.

Recommended AI News: Ocrolus Adds OpenAI GPT Embeddings for Deeper Automation in Financial Document Analysis

The collaboration is designed to create a platform that proactively monitors the rehabilitation process of patients following the Zephyr Valve procedure and rapidly identifies early signs of exacerbations. By improving patient monitoring and support during the critical rehabilitation period after the procedure, this initiative strives to enhance patient outcomes and provide peace of mind to both patients and healthcare providers.

Recommended AI News: Cognizant and Google Cloud Expand Alliance to Bring AI to Enterprise Clients

[To share your insights with us, please write to sghosh@martechseries.com]

The post RespirAI Enters Into Know-How Agreement With Mayo Clinic for Development of AI Respiratory Platform appeared first on AiThority.

biomarkers
medical
healthcare
ai